Personalized medicine for the brain

BEAM combines EEG with automated neurocognitive tests and computes biomarkers referenced to our extensive normative database.

These analytics assist in differentiating dementia sub-types, quantifying severity of cognitive decline, tracking disease progression and assessing treatment efficacy.

BEAM™ biomarkers include


  • Mild Cognitive Impairment
  • Alzheimer’s
  • Lewy Body
  • Parkinson’s
  • Huntington’s


  • Depression
  • Anxiety
  • PTSD


  • Proven & objective
  • Sensitive for early detection
  • Non-invasive
  • Easy to administer
  • 1/10th the cost of MRI or PET
  • Suitable for frequent screening
  • Reimbursable under existing CPT codes

Imaging Modalities

  • EEG / ERP
  • ECG
  • Cognitive performance

Healthy Aging to Disease Comparison



Healthy aging can be differentiated from neurodegenerative decline

BEAM – Sample Individual Patient Reports

Patient 1 – Healthy

Patient 2 – Alzheimer’s

is a fully mobile wireless device designed for use in any setting with rapid setup. New technicians can be trained and certified in a 4-hour session on-site.

Case Study

64-year-old man – longitudinal study
Dx: amnestic MCI

Year 1 Patient scored 29 on MMSE
Year 2 Patient scored 25 on MMSE

MMSE score of 25 or higher is considered Normal

Although Patient’s Year 2 MMSE indicates Normal, his BEAM biosignature clearly shows he has moved from healthy to MCI. This patient should be monitoring his health and may be a candidate for newly available treatment.

Get in touch
Contact Us